glp 1 and muscle loss Impact of GLP- Receptor Agonist Therapy in Patients High Risk for Sarcopenia | Current Nutrition Reports Using glp-1 receptor agonists for

Triple agonist (GLP-1/GIP/Glucagon), under clinical investigation

Researchers are exploring whether semaglutide drugs like Ozempic and Wegovy could help prevent cognitive decline

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase depression risk, a new review concludes.

Delve into the perspectives of employers and health plans on obesity, GLP-1 coverage rates, and concerns about off-label use.

One of the largest US health insurers is ending coverage of GLP-1 weight-loss drugs for its employees but will continue covering them for people with type 2 diabetes.

With the emergence of GLP-1s, there is a divide between patient perception of the medication and how clinical science views it